Topics
Latest
AI
Amazon
Image Credits:Abraham Gonzalez Fernandez / Getty Images
Apps
Biotech & Health
mood
Image Credits:Abraham Gonzalez Fernandez / Getty Images
Cloud Computing
Commerce
Crypto
Image Credits:ImpriMed
Enterprise
EVs
Fintech
Fundraising
Gadgets
Gaming
Government & Policy
computer hardware
Layoffs
Media & Entertainment
Meta
Microsoft
Privacy
Robotics
Security
Social
Space
Startups
TikTok
transport
speculation
More from TechCrunch
Events
Startup Battlefield
StrictlyVC
Podcasts
Videos
Partner Content
TechCrunch Brand Studio
Crunchboard
Contact Us
ImpriMed , a California - based preciseness medicine startup , make AI - power dog cancer treatment technology that helps veterinary identify the most suited drugs for individual dogtooth and feline rip Crab .
The startup , which revolve around on meliorate handling result of dogs and true cat with cancer first , now aims to expound its precision medical specialty technology for human oncology applications .
“ The ex - vivo live - cellular telephone technologies we developed for canine tooth blood cancers are well - put on to the absolute majority of case of human stemma malignant neoplastic disease as well as feline blood cancers , ” co - founder and chief executive officer Sungwon Lim said in an audience with TechCrunch . “ Also , the proved know - how acquired from evolve AI algorithms in veterinary oncology streamline the construction of novel predictive models in human oncology . The veterinary - to - human expansion is happening now at ImpriMed and will ensue in commercialisation in one - two years . ”
Lim , who previously work in the cancer drug manufacture for more than a decennary , co - founded ImpriMed with his old friend Jamin Koo in 2017 . The twosome had Ph.D. degree from Stanford after receiving undergraduate degrees in chemical and biomolecular engineering at KAIST in South Korea . While put to work in the cancer drug discourse diligence , he came up with the same question : “ Are we expeditiously apply all the tools we presently have in our aesculapian toolbox ? ”
“ People who are endure from cancer and desperately need treatment powerful now do n’t have time to wait over 10 old age for a new drug , ” Lim said . “ Of course , it is essential to bear on searching for new , better therapeutic options , but new drug exploitation should not be the only way to improve Cancer the Crab tending . ”
The carbon monoxide gas - founders want to apply existing drugs to personalise cancer discourse regime for case-by-case patient . Lim tell that ImpriMed ’s AI - power personalized drug efficacy prevision table service enables oncologists to identify effective anticancer medicines that are extremely likely to play for a specific patient before the Dr. makes a decision .
ImpriMed of late closed $ 23 million in its Series A round , which fetch its sum upraise to $ 35 million since its origin . SoftBank Ventures Asia led the Series A , with participation from strategic investor SK Telecom and other financial investor , including HRZ Han River Partners , KDB Silicon Valley , Ignite Innovation Fund , Samyang Chemical Group and Murex Partners .
Join us at TechCrunch Sessions: AI
Exhibit at TechCrunch Sessions: AI
The kit look to partner with its strategic investor , SK Telecom , one of South Korea ’s big telco company , which builds an AI - based veterinary disco biscuit - ray picture diagnosing technology called X - Caliber . Last twelvemonth , ImpriMed graduate fromthe Mayo Clinic Platform Accelerate Programto “ validate its AI example using a adult human patient role database provided by the program , ” the caller say .
ImpriMed ’s veterinary armed service are fully commercialized , offer five eye tooth and three feline services and generating revenue . The startup say more than 350 vet in the U.S. have used its service . ( There areapproximately 600 control board - certified veterinary oncologists throughout the U.S. )
This is how its B2B avail figure out : First , the oncologist pull together live cancer electric cell and blood sample from the affected role and beam the samples to ImpriMed ’s research lab in California . The society then measure how the patient ’s hot Crab cells respond to dissimilar anticancer drugs , partly by using AI to aggregate these mensuration with other biologic data and foretell which drugs are most likely to be effective for the patient role ’s Cancer the Crab . ImpriMed provides the composition to the order veterinary surgeon seven sidereal day after receiving the sample distribution at the research lab , according to the company .
For human precision oncology , its AI software formultiple myeloma , a rare rake genus Cancer , is in the process of approval , aiming to commercialize in 2025 , Lim told TechCrunch . It also offer a live - jail cell - based drug sensitivity test that lets pharmaceuticals measure the efficacy of new drug compounds on actual patients ’ live cells of their target cancer .
“ We currently extend this contract bridge research organization service for eyetooth lymphoma and aim to market the service for human acute myeloid leukemia and non - Hodgkin ’s lymphoma before the end of 2024 , ” the CEO said .
Challenges ImpriMed is trying to solve
ImpriMed is tackling a significant challenge in veterinary practice of medicine : handle lymphoma , the most common Crab diagnosed in dogs , more effectively , Lim said . As every dog is unique , formal handling can be expensive , pasture from $ 10,000 to $ 25,000 , and does n’t sour equally well for all .
“ Each cancer patient has a different reply to drug , [ even withstandard chemotherapy communications protocol CHOP ] ; each lymphoma patient answer differently , ” Lim proceed . “ rather of a one - size of it - fits - all approaching , its [ AI - powered personalized ] technology not only increases the chances of successful treatment but can potentially reduce unnecessary price and side effects from less good treatment . ”
The company pronounce it helped more than 5,000 dogs with lymphoma with its services and take in “ real - world clinical issue follow - up data from more than half of those patients . ” In improver , it ran further validation with 2,000 humans with blood cancers and Mayo Clinic Platform ’s database of 3 million patient .
“ Ourrecent field demonstratesthat ImpriMed ’s AI correctly identifies effective lymphoma drug for single frankfurter with relapsed atomic number 5 - cell lymphoma , leading to a 4 - fold higher consummate reply pace and a medial survival metre 3 - fold longer than for those who receive treatment that did n’t align with ImpriMed ’s prediction , significantly improving treatment outcomes , ” the companionship CEO said .
Competitors include pet preciseness medicine companies like FidoCure and Vidium Animal Health and party that apply live Crab cells for functional precision music like Notable Labs and Xilis . ImpriMed ’s unique metier is “ the power to develop and comprise AI models into the personalized medication service workflow , ” according to Lim . Developing and incorporating AI models into the individualized medicine service workflow requires a large amount of clinical outcome data that other companies skin with collecting , he tot .
The company will use the latest funding to flourish its drug response prediction engineering beyond veterinary medicine into human oncology , increase its manpower and broaden its pipelines in business organisation development . It has about 40 staff .
Xilis believes cultivating micro - tumors may hold the key fruit to more effective cancer treatments
Dog Crab discourse inauguration raise $ 5 million from Andreessen Horowitz and others
